Don't get shut down

Why peptide payments get declined — and how to fix the causes

Card declines on a research-peptide storefront come from four distinct sources. How to tell which one you're hitting, what each one actually means, and what fixes it.

A customer tries to pay, the card is refused, and the order is gone. On a research-peptide storefront this happens more than it does elsewhere — and founders usually treat it as one problem when it's actually four, with four different fixes.

Diagnosing which one you're hitting is most of the work.

The short version
  • Declines come from four sources: the issuing bank, your processor's risk rules, the acquirer's category restrictions, or plain technical failure. They look identical to the customer.
  • Response codes tell you which. Get them out of your gateway before theorising.
  • A rising decline rate frequently precedes a processor review rather than following one. Treat a sharp increase as an early warning.
  • The single cheapest fix is a recognisable billing descriptor — it reduces both declines and disputes.
  • If the acquirer is restricting the category, no amount of checkout optimisation helps. That's an underwriting problem.

The four causes

1. Issuer declines

The customer's own bank refuses the transaction. This is the most common cause and the one you control least.

Issuing banks run their own fraud models. A transaction can be declined for insufficient funds, an unusual merchant category, a card-not-present transaction that doesn't match the customer's pattern, an international merchant, a mismatched billing address, or simply an opaque internal risk score.

You cannot change a bank's model. You can reduce how suspicious your transaction looks:

  • A recognisable billing descriptor. If it says something unrelated to what the customer thinks they bought, both declines and disputes rise.
  • Accurate AVS and CVV data collection. Address mismatches trigger declines that clean data avoids.
  • A checkout that doesn't look improvised. Poorly assembled checkouts trip fraud heuristics.
  • Sensible order sizing. Unusually large first orders decline more often.

2. Processor risk rules

Your own processor blocks the transaction before it reaches the issuer, based on velocity limits, ticket-size ceilings, geographic restrictions, or fraud scoring.

These are usually configurable — but they're set the way they are because of your risk profile. Loosening them is a conversation with your processor, not a setting you should quietly change. And if they're declining a lot of your volume, that itself tells you something about how they view the account.

3. Acquirer category restrictions

The account isn't underwritten for what you're actually selling.

This is the serious one. If a mainstream aggregator is progressively declining your transactions, it frequently means their systems have begun classifying the business correctly — and a full risk review may be underway. Declines can be the first visible symptom of a process that ends in a freeze.

4. Technical and data failures

Unglamorous and genuinely common: expired cards, mistyped numbers, gateway timeouts, misconfigured 3-D Secure, currency mismatches, a checkout that breaks on mobile Safari.

These are entirely fixable and often account for a surprising share of "declines" that were never risk decisions at all.

Diagnosing which one you have

Stop guessing and get the response codes from your gateway. Every decline carries one, and they cluster:

What you seeLikely causeWhat to do
Scattered declines across many issuers, no patternIssuer-side risk modelsImprove descriptor, AVS/CVV data, checkout quality
Declines cluster on large orders or repeat velocityYour processor's risk rulesTalk to your processor about limits
Decline rate rising steadily over weeks on an aggregatorCategory restriction / review underwayMove to proper underwriting, urgently
Declines on specific cards, browsers, or amountsTechnical / configurationFix the gateway and checkout

Two useful habits: track decline rate as a weekly metric rather than noticing it anecdotally, and segment by issuer and order size. A rate that's flat and slightly elevated is a cost of doing business. A rate that's climbing is a signal.

What actually reduces declines

Fix the billing descriptor first. It's the cheapest, highest-leverage change available. It should clearly name the brand the customer believes they bought from. This reduces issuer declines and "I don't recognise this charge" disputes — and your dispute ratio is what decides your reserve terms.

Collect and pass complete data. Full billing address, CVV, correct currency. Incomplete data raises risk scores at every step in the chain.

Set clear expectations at checkout. Tell customers what the charge will appear as. Confirm the order by email immediately. Provide tracking. Most "declines" that turn into support tickets are actually confusion.

Offer a fallback path. Some orders will not go through on card regardless of what you do. An inquiry or invoice option recovers revenue that would otherwise be lost entirely — see the inquiry-based ordering model. For higher-value orders, many buyers in this category prefer invoicing anyway.

Get properly underwritten. If the underlying issue is that your account isn't approved for what you sell, everything above is optimisation around a structural problem. A high-risk merchant account with a processor that underwrites research peptides deliberately removes the category-restriction cause entirely.

The connection to freezes

Declines, disputes and freezes are the same story at different stages.

High decline rates often indicate your transactions look risky to the payments chain. High dispute rates confirm it. Sustained high ratios in either trigger review — and for a research-peptide account on a mainstream aggregator, review tends to end in a category decision rather than a warning.

So the work that reduces declines is largely the same work that protects the account: accurate descriptors, clean data, fast support, tracked delivery, honest product pages, and a refund policy you follow. A refund costs you one order. A chargeback costs you the order, a fee, and a mark on the ratio that decides your reserve — and enough of them cost you the account.

The takeaway

Peptide payment declines aren't one problem. They're four, and the fix depends entirely on which one you're actually experiencing.

Pull the response codes. If it's issuer-side, fix your descriptor and your data. If it's your processor's rules, have the conversation. If it's technical, fix the gateway. And if the decline rate is climbing steadily on a mainstream aggregator, treat that as the early warning it usually is — and get underwritten properly before the review completes rather than after.

Questions founders ask

Why do peptide payments get declined?

Four distinct causes: the issuing bank declining the card, the processor blocking the transaction on risk rules, the acquirer restricting your merchant category, or ordinary technical and data failures. They look identical to the customer but need completely different fixes.

Can I do anything about issuer declines?

Some. You can't control an individual bank's risk model, but a recognisable billing descriptor, accurate address data, and a checkout that doesn't look suspicious all reduce the rate. Offering an alternative payment path recovers orders you'd otherwise lose.

Do high decline rates put my merchant account at risk?

They can. Sustained high decline and dispute ratios are exactly what triggers a risk review, and a review of a research-peptide account often ends in a category decision. Declines are worth fixing for that reason alone, not just lost revenue.

Is a high decline rate normal for peptide brands?

Somewhat elevated rates are common in high-risk categories. But a sharply rising rate is a signal worth investigating immediately — it often precedes a processor review rather than following one.

Will switching processors fix declines?

Only if the cause is processor-side. If issuers are declining your transactions, switching acquirers changes little. Diagnose the source first — the response codes tell you which of the four causes you're dealing with.

Ready to build the brand that ranks?

One call. We'll tell you exactly what we'd build and what it takes to get you found. Scope is handled privately on the call.

Book a discovery call →